Cost-Effectiveness of Screening Mammography Beyond Age 75 Years A Cost-Effectiveness Analysis

Background: The cost-effectiveness of screening mammography beyond age 75 years remains unclear. Objective: To estimate benefits, harms, and cost-effectiveness of extending mammography to age 80, 85, or 90 years according to comorbidity burden. Design: Markov microsimulation model. Data Sources: SEER (Surveillance, Epidemiology, and End Results) program and Breast Cancer Surveillance Consortium. Target Population: U.S. women aged 65 to 90 years in groups defined by Charlson comorbidity score (CCS). Time Horizon: Lifetime. Perspective: National health payer. Outcome Measures: Breast cancer death, survival, and costs. Results of Base-Case Analysis: Extending biennial mammography from age 75 to 80 years averted 1.7, 1.4, and 1.0 breast cancer deaths and increased days of life gained by 5.8, 4.2, and 2.7 days per 1000 women for comorbidity scores of 0, 1, and 2, respectively. Annual mammography beyond age 75 years was not cost-effective, but extending biennial mammography to age 80 years was ($54 000, $65000, and $85000 per quality-adjusted life-year [QALY] gained for women with CCSs of 0, 1, and >= 2, respectively). Overdiagnosis cases were double the number of deaths averted from breast cancer. Results of Sensitivity Analysis: Costs per QALY gained were sensitive to changes in invasive cancer incidence and shift of breast cancer stage with screening mammography. Limitation: No randomized controlled trials of screening mammography beyond age 75 years are available to provide model parameter inputs. Conclusion: Although annual mammography is not cost-effective, biennial screening mammography to age 80 years is; however, the absolute number of deaths averted is small, especially for women with comorbidities. Women considering screening beyond age 75 years should weigh the potential harms of overdiagnosis versus the potential benefit of averting death from breast cancer.